FDA’s Breakthrough Designations Face Question Of Review Resources
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Woodcock says FDA will manage breakthrough applications along with its entire portfolio of submissions, but some stakeholders express concern about whether the demands of the exceedingly popular program will affect the agency’s handling of other applications.